Blog: Can AI-Guided Cannabinoid Care Become Reliable?
AI-guided cannabinoid care may eventually help explain why patients respond so differently to similar products, doses, and diagnoses. This essay examines how longitudinal data, product chemistry, physiology, and clinical outcomes could support better…
Can the Endocannabinoid System Help Explain Bruxism? What a New Neurobiological Model Proposes
A July 2026 Frontiers in Neuroscience paper proposes the endocannabinoid system bruxism neuromodulation hypothesis, suggesting ECS may regulate brain circuits behind bruxism. This is a translational model, not a clinical trial, highlighting a promising…
Medicinal Cannabis and Fibromyalgia: Biomarker Trial Insights
The fibromyalgia endocannabinoid biomarkers trial found no significant changes in peripheral blood markers after oral THC:CBD cannabis oil treatment, despite reported pain relief. This highlights the complexity of monitoring cannabis effects in…
Why Healthcare Providers Are Well Positioned to Talk to Patients About Medical Marijuana
Healthcare providers cannabis policy clarifies that discussing medical marijuana with patients is legally permissible despite federal restrictions on prescribing. This distinction encourages open, informed conversations to guide patient use safely.…
Cannabinoid Immune Modulation and Autoimmune Disease: A Literature Review
This literature review examines cannabinoid immune modulation and its potential impact on autoimmune disease. It highlights CB2 receptor biology and laboratory evidence while noting the scarcity of controlled clinical trials. The review provides a clear…
THC and PTSD: Insights from a Dose-Finding Clinical Trial on Cognitive Reappraisal
A THC dose-finding clinical trial standardized in adults with PTSD revealed dose-dependent reductions in prefrontal brain activity during cognitive reappraisal. Despite these neural changes, self-reported emotional ratings remained unchanged. This…
THC and PTSD Emotion Regulation: What a New Brain-Imaging Study Actually Found
The acute oral THC cognitive reappraisal PTSD study found that 5 mg and 10 mg doses reduced prefrontal brain activation during emotion regulation in adults with PTSD. Despite these neural changes, no improvement in self-reported negative affect was…
Understanding Low-Dose CBD: Clinical Pharmacology and Therapeutic Insights
The low-dose cannabidiol clinical pharmacology review reveals that common low doses of CBD usually show limited and inconsistent therapeutic value. Despite this, low-dose CBD still raises important questions about drug interactions and clinical…
CBD, CBN, and THC: What a New Narrative Review Says About Psychiatric Risk and Benefit
CBD CBN THC psychiatric effects were compared in a new narrative review spanning PubMed, Scopus, and Web of Science through March 2026. CBD showed preclinical promise but unproven clinical benefit, and CBN evidence remained too thin for any…
Insights on Cannabinoid Exposure in Substance Use Disorders
This 2026 review on cannabinoid exposure substance use disorders analyzes 97 studies with over 41,000 participants. It finds cannabinoids offer short-term symptom relief but lack durable efficacy for abstinence or relapse prevention. The evidence guides…